franckreporter/E+ via Getty Images
Maravai Life Sciences (NASDAQ: MROV) could be worth $15 to $20 per share in a potential acquisition based on previous transactions, according to an RBC analyst, after a report that Repligen (RGEN) has made an offer for the vaccine reagent vendor.
Maravai Stock (MRVI)) jump 23% After Reuters report on Repligen (Argin) The acquisition approach on Friday. There is no certainty that Maravai (Collapse) will accept the deal, according to the report.
“While we believe MRVI is a good acquisition candidate given its unique product offering, we are not sure if RGEN is a natural buyer,” RBC analyst Connor McNamara wrote in a note Friday.
Reuters also reported that Repligen (REGN) is deciding whether to divest some of Marvi’s businesses if it acquires the company. decreased by 10% Following the report.
McNamara added that Repligen’s (RGEN) potential deal to buy Maravai (MRVI) would require issuing shares, even if the combined entity would raise about 3x its most recent period’s EBITDA.
“Investors may be reluctant to own the combined entity at around 45x 2025 EBITDA given the potential disruption to integration,” McNamara, who has an outperform rating and a $15 price target on MRVI, wrote in the note.